SUBSCRIPTION AGREEMENTSubscription Agreement • September 27th, 2017 • Aspyron Inc • Wyoming
The securities offered hereby are highly speculative. Investing in shares of Aspyron Inc involves significant risks. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following this offering, it may not continue.
CONTRACT OF MANUFACTUREContract of Manufacture • September 27th, 2017 • Aspyron Inc
Contract Packaging Agreement between EMS Contract Packaging (A Division of EMS Aquisition Corp,), 1560 Industry Road, Hatfield, PA 19440 {hereinafter known as "Contract Packager") and Aspyron, Inc, 763 Linden Ave, Suite 2, Rochester, NY 1462S, {hereinafter known as 'Customer"). Whereby, the Customer desires to have the Contract Packager manufacture and package the Over The Counter (OTC) drug products known as Sinus Max* Nasal Spray and Kool Blast Sore Throat Spray ("Aspyron Products") in accordance with the Customer's formulas and specifications.
Supply and Private Label AgreementSupply and Private Label Agreement • September 27th, 2017 • Aspyron Inc • New York
AGREEMENT, made as of the first day of September, 2015, by and between Aphex BioCleanse Systems, Inc., a Florida corporation incorporated under the laws of the State of Florida, with a place of business at 15 Fishers Road, Suite 111, Pittsford, New York 14534, (hereinafter referred to as “APHEX”), and Aspyron, Inc. with a place of business at 763 Linden Avenue, Suite 2, Rochester, NY 14625, (hereinafter referred to as “ASPYRON”), as follows:
